Repare Therapeutics (RPTX) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart

RPTX Stock Forecast

Repare Therapeutics stock forecast is as follows: an average price target of $18.33 (represents a 536.46% upside from RPTX’s last price of $2.88) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.

RPTX Price Target

The average price target for Repare Therapeutics (RPTX) is $18.33 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $30.00 to $10.00. This represents a potential 536.46% upside from RPTX's last price of $2.88.

RPTX Analyst Ratings

Buy

According to 5 Wall Street analysts, Repare Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for RPTX stock is 0 'Strong Buy' (0.00%), 4 'Buy' (80.00%), 1 'Hold' (20.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Repare Therapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Sep 04, 2024	Robert Burns	H.C. Wainwright	$10.00	$2.81	255.87%	247.22%
Feb 03, 2023	-	Morgan Stanley	$15.00	$13.14	14.16%	420.83%
Nov 17, 2022	-	H.C. Wainwright	$25.00	$17.00	47.06%	768.06%
Jun 20, 2022	Joseph Catanzaro	Piper Sandler	$30.00	$13.27	126.07%	941.67%

Row per page

Go to

The latest Repare Therapeutics stock forecast, released on Sep 04, 2024 by Robert Burns from H.C. Wainwright, set a price target of $10.00, which represents a 255.87% increase from the stock price at the time of the forecast ($2.81), and a 247.22% increase from RPTX last price ($2.88).

Repare Therapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	-	1	1
Avg Price Target	-	$10.00	$10.00
Last Closing Price	$2.88	$2.88	$2.88
Upside/Downside	-100.00%	247.22%	247.22%

In the current month, the average price target of Repare Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Repare Therapeutics's last price of $2.88. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Sep 16, 2024	Piper Sandler	Overweight	Overweight	Hold
Sep 04, 2024	H.C. Wainwright	Buy	Buy	Hold
Jun 09, 2023	Daiwa	-	Buy	Upgrade
Feb 03, 2023	Morgan Stanley	-	Equal-Weight	Downgrade
Jun 20, 2022	Piper Sandler	Overweight	Overweight	Hold
Jun 02, 2022	Roth Capital	-	Buy	Initialise

Row per page

Go to

Repare Therapeutics's last stock rating was published by Piper Sandler on Sep 16, 2024. The company gave RPTX a "Overweight" rating, the same as its previous rate.

Repare Therapeutics Financial Forecast

Repare Therapeutics Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
Revenue	-	-	-	-	-	-	-	-	-	-	-	$5.68M	$18.20M	$112.55M	$679.00K	$408.00K	$6.88M	$278.00K	$279.00K	$166.00K	$135.00K	-
Avg Forecast	$2.92M	$2.34M	$2.34M	$2.34M	$2.73M	$2.73M	$2.92M	$38.40M	$18.93M	$6.31M	$7.01M	$5.14M	$9.72M	$1.98M	$5.43M	$2.35M	$3.82M	$244.75K	$1.00M	$1.25M	$2.50M	$1.25M
High Forecast	$4.45M	$3.56M	$3.56M	$3.00M	$4.63M	$2.82M	$2.92M	$58.41M	$65.40M	$6.31M	$10.67M	$7.82M	$14.78M	$1.98M	$5.43M	$2.35M	$3.82M	$244.75K	$1.00M	$1.25M	$2.50M	$1.25M
Low Forecast	$1.26M	$1.01M	$1.01M	$1.20M	$1.02M	$2.64M	$2.92M	$16.57M	$2.97M	$6.31M	$3.03M	$2.22M	$4.19M	$1.98M	$5.43M	$2.35M	$3.82M	$244.75K	$1.00M	$1.25M	$2.50M	$1.25M
# Analysts	1	1	1	3	4	2	4	4	5	4	4	4	3	3	3	3	4	4	4	4	4	4
Surprise %	-	-	-	-	-	-	-	-	-	-	-	1.10%	1.87%	56.98%	0.13%	0.17%	1.80%	1.14%	0.28%	0.13%	0.05%	-

Repare Therapeutics's average Quarter revenue forecast for Jun 23 based on 4 analysts is $7.01M, with a low forecast of $3.03M, and a high forecast of $10.67M. RPTX's average Quarter revenue forecast represents a 23.53% increase compared to the company's last Quarter revenue of $5.68M (Mar 23).

Repare Therapeutics EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	1	1	1	3	4	2	4	4	5	4	4	4	3	3	3	3	4	4	4	4	4	4
EBITDA	-	-	-	-	-	-	-	-	-	$-38.42M	$-12.26M	$-34.63M	$-19.23M	$73.76M	$-38.35M	$-34.30M	$-28.23M	$-31.18M	$-26.28M	$-21.17M	$-16.45M	$-13.28M
Avg Forecast	$-1.25M	$-999.25K	$-999.25K	$-999.25K	$-1.17M	$-1.17M	$-1.25M	$-16.40M	$-8.08M	$-2.69M	$-3.00M	$-2.20M	$-4.15M	$-850.24K	$-2.34M	$-35.40M	$-1.65M	$-105.36K	$-430.50K	$-18.26M	$-1.08M	$-538.12K
High Forecast	$-538.97K	$-431.18K	$-431.18K	$-512.44K	$-434.72K	$-1.13M	$-1.25M	$-7.08M	$-1.27M	$-2.69M	$-1.29M	$-947.95K	$-1.79M	$-850.24K	$-2.34M	$-28.32M	$-1.65M	$-105.36K	$-430.50K	$-14.61M	$-1.08M	$-538.12K
Low Forecast	$-1.90M	$-1.52M	$-1.52M	$-1.28M	$-1.98M	$-1.21M	$-1.25M	$-24.94M	$-27.93M	$-2.69M	$-4.56M	$-3.34M	$-6.31M	$-850.24K	$-2.34M	$-42.48M	$-1.65M	$-105.36K	$-430.50K	$-21.92M	$-1.08M	$-538.12K
Surprise %	-	-	-	-	-	-	-	-	-	14.26%	4.09%	15.76%	4.64%	-86.75%	16.41%	0.97%	17.15%	295.91%	61.05%	1.16%	15.28%	24.68%

3 analysts predict RPTX's average Quarter EBITDA for Dec 22 to be $-4.15M, with a high of $-1.79M and a low of $-6.31M. This is -105.63% lower than Repare Therapeutics's previous annual EBITDA (Sep 22) of $73.76M.

Repare Therapeutics Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	1	1	1	3	4	2	4	4	5	4	4	4	3	3	3	3	4	4	4	4	4	4
Net Income	-	-	-	-	-	-	-	-	-	$-51.48M	$-11.95M	$-34.94M	$-31.66M	$75.46M	$-38.09M	$-34.76M	$-28.29M	$-30.89M	$-26.31M	$-21.42M	$-15.26M	$-13.75M
Avg Forecast	$-34.04M	$-31.50M	$-30.93M	$-31.63M	$-35.21M	$-36.98M	$-36.88M	$667.10K	$-15.22M	$-36.46M	$-34.28M	$-34.33M	$-30.09M	$909.56K	$-33.05M	$-35.97M	$-31.41M	$-30.14M	$-25.68M	$-18.48M	$-16.81M	$-16.06M
High Forecast	$-8.88M	$-8.22M	$-8.07M	$-29.32M	$-30.96M	$-9.65M	$-9.62M	$673.17K	$7.88M	$-9.51M	$-8.95M	$-8.96M	$-7.85M	$909.56K	$-33.05M	$-28.78M	$-31.41M	$-30.14M	$-25.68M	$-14.78M	$-16.81M	$-16.06M
Low Forecast	$-57.09M	$-52.83M	$-51.87M	$-34.33M	$-44.54M	$-62.02M	$-61.86M	$661.03K	$-24.19M	$-61.15M	$-57.50M	$-57.58M	$-50.47M	$909.56K	$-33.05M	$-43.16M	$-31.41M	$-30.14M	$-25.68M	$-22.17M	$-16.81M	$-16.06M
Surprise %	-	-	-	-	-	-	-	-	-	1.41%	0.35%	1.02%	1.05%	82.96%	1.15%	0.97%	0.90%	1.03%	1.02%	1.16%	0.91%	0.86%

Repare Therapeutics's average Quarter net income forecast for Dec 22 is $-30.09M, with a range of $-50.47M to $-7.85M. RPTX's average Quarter net income forecast represents a -139.87% decrease compared to the company's last Quarter net income of $75.46M (Sep 22).

Repare Therapeutics SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	1	1	1	3	4	2	4	4	5	4	4	4	3	3	3	3	4	4	4	4	4	4
SG&A	-	-	-	-	-	-	-	-	-	$7.87M	$8.72M	$8.53M	$7.94M	$7.90M	$7.94M	$8.78M	$7.64M	$6.60M	$6.74M	$5.24M	$4.79M	$4.00M
Avg Forecast	$65.30M	$52.24M	$52.24M	$52.24M	$61.02M	$61.02M	$65.29M	$857.27M	$422.62M	$140.87M	$156.59M	$114.85M	$216.92M	$44.09M	$121.22M	$52.50M	$85.35M	$5.46M	$22.32M	$27.91M	$55.81M	$27.91M
High Forecast	$99.32M	$79.46M	$79.46M	$66.97M	$103.41M	$63.04M	$65.30M	$1.30B	$1.46B	$140.87M	$238.18M	$174.69M	$329.94M	$44.09M	$121.22M	$52.50M	$85.35M	$5.46M	$22.32M	$27.91M	$55.81M	$27.91M
Low Forecast	$28.18M	$22.54M	$22.54M	$26.79M	$22.73M	$59.00M	$65.29M	$369.91M	$66.37M	$140.87M	$67.57M	$49.56M	$93.60M	$44.09M	$121.22M	$52.50M	$85.35M	$5.46M	$22.32M	$27.91M	$55.81M	$27.91M
Surprise %	-	-	-	-	-	-	-	-	-	0.06%	0.06%	0.07%	0.04%	0.18%	0.07%	0.17%	0.09%	1.21%	0.30%	0.19%	0.09%	0.14%

Repare Therapeutics's average Quarter SG&A projection for Dec 23 is $422.62M, based on 5 Wall Street analysts, with a range of $66.37M to $1.46B. The forecast indicates a 5271.33% rise compared to RPTX last annual SG&A of $7.87M (Sep 23).

Repare Therapeutics EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	1	1	1	3	4	2	4	4	5	4	4	4	3	3	3	3	4	4	4	4	4	4
EPS	-	-	-	-	-	-	-	-	-	$-1.22	$-0.28	$-0.83	$-0.76	$1.80	$-0.91	$-0.83	$-0.70	$-0.83	$-0.71	$-0.58	$-0.41	$-0.37
Avg Forecast	$-0.80	$-0.74	$-0.73	$-0.75	$-0.83	$-0.87	$-0.87	$0.02	$-0.36	$-0.86	$-0.81	$-0.81	$-0.71	$0.02	$-0.78	$-0.86	$-0.74	$-0.71	$-0.60	$-0.51	$-0.40	$-0.38
High Forecast	$-0.21	$-0.19	$-0.19	$-0.69	$-0.73	$-0.23	$-0.23	$0.02	$0.19	$-0.22	$-0.21	$-0.21	$-0.18	$0.02	$-0.78	$-0.86	$-0.74	$-0.71	$-0.60	$-0.51	$-0.40	$-0.38
Low Forecast	$-1.34	$-1.24	$-1.22	$-0.81	$-1.05	$-1.46	$-1.46	$0.02	$-0.57	$-1.44	$-1.35	$-1.36	$-1.19	$0.02	$-0.78	$-0.86	$-0.74	$-0.71	$-0.60	$-0.51	$-0.40	$-0.38
Surprise %	-	-	-	-	-	-	-	-	-	1.42%	0.35%	1.03%	1.07%	84.00%	1.17%	0.97%	0.95%	1.17%	1.17%	1.15%	1.04%	0.98%

According to 3 Wall Street analysts, Repare Therapeutics's projected average Quarter EPS for Dec 22 is $-0.71, with a low estimate of $-1.19 and a high estimate of $-0.18. This represents a -139.38% decrease compared to RPTX previous annual EPS of $1.80 (Sep 22).

Repare Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
RPTX	Repare Therapeutics	$2.88	$18.33	536.46%	Buy
ACCD	Accolade	$3.49	$14.81	324.36%	Buy
RLAY	Relay Therapeutics	$4.80	$19.40	304.17%	Buy
NRIX	Nurix Therapeutics	$22.79	$32.20	41.29%	Buy
FUSN	Fusion Pharmaceuticals	$21.55	$15.25	-29.23%	Hold

RPTX Forecast FAQ

Is Repare Therapeutics a good buy?

Yes, according to 5 Wall Street analysts, Repare Therapeutics (RPTX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 80.00% of RPTX's total ratings.

What is RPTX's price target?

Repare Therapeutics (RPTX) average price target is $18.33 with a range of $10 to $30, implying a 536.46% from its last price of $2.88. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Repare Therapeutics stock go up soon?

According to Wall Street analysts' prediction for RPTX stock, the company can go up by 536.46% (from the last price of $2.88 to the average price target of $18.33), up by 941.67% based on the highest stock price target, and up by 247.22% based on the lowest stock price target.

Can Repare Therapeutics stock reach $4?

RPTX's average twelve months analyst stock price target of $18.33 supports the claim that Repare Therapeutics can reach $4 in the near future.

What are Repare Therapeutics's analysts' financial forecasts?

Repare Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $46.79M (high $68.79M, low $23.16M), average EBITDA is $-19.981M (high $-9.888M, low $-29.375M), average net income is $-108M (high $-49.563M, low $-168M), average SG&A $1.04B (high $1.54B, low $516.93M), and average EPS is $-2.553 (high $-1.167, low $-3.952). RPTX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $9.94M (high $14.57M, low $4.48M), average EBITDA is $-4.247M (high $-1.914M, low $-6.221M), average net income is $-128M (high $-54.486M, low $-196M), average SG&A $222.02M (high $325.21M, low $100.05M), and average EPS is $-3.017 (high $-1.283, low $-4.62).

Did the RPTX's actual financial results beat the analysts' financial forecasts?

Based on Repare Therapeutics's last annual report (Dec 2022), the company's revenue was $131.83M, beating the average analysts forecast of $19.47M by 576.98%. Apple's EBITDA was $-20.104M, missing the average prediction of $-42.74M by -52.96%. The company's net income was $-29.047M, missing the average estimation of $-98.195M by -70.42%. Apple's SG&A was $32.56M, missing the average forecast of $434.73M by -92.51%. Lastly, the company's EPS was $-0.69, missing the average prediction of $-2.322 by -70.28%. In terms of the last quarterly report (Mar 2023), Repare Therapeutics's revenue was $5.68M, beating the average analysts' forecast of $5.14M by 10.37%. The company's EBITDA was $-34.625M, beating the average prediction of $-2.197M by 1476.11%. Repare Therapeutics's net income was $-34.941M, beating the average estimation of $-34.326M by 1.79%. The company's SG&A was $8.53M, missing the average forecast of $114.85M by -92.57%. Lastly, the company's EPS was $-0.83, beating the average prediction of $-0.809 by 2.65%